Newsroom

BRIDGING SCIENCE AND PATIENTS

Media

  • From Bench to Bedside: The Story about BBT-401

    This is the story all about science, discovery and development of BBT-401, the first-in-class Pellino-1 inhibitor. BBT-401, an experimental drug for ulcerative colitis (UC) is in the Phase 2a in the United States.

    2020.06.25

1